Literature DB >> 33191714

LncRNA XIST promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by downregulating miR-27b-3p.

S Q Ma1, Y C Wang2, Y Li3, X Y Li4, J Yang5, Y M Sheng6.   

Abstract

Chemotherapy resistance has become a major obstacle to effective treatment of human cancer. This study aimed to investigate the effect of lncRNA XIST on cell proliferation and cisplatin (CDDP) of oral squamous cell carcinoma (OSCC). RT-qPCR and Western blot analysis were used to detect mRNA and protein expression. CCK-8 and flow cytometry assays were explored to evaluate CDDP sensitivity in OSCC cells. The relationship between lncRNA XIST and miR-27b-3p was confirmed by luciferase reporter assay. The results showed that lncRNA XIST was upregulated in OSCC tissues, cell lines, and CDDP-resistant OSCC cells. Functionally, upregulation of lncRNA XIST promoted cell proliferation, enhanced CDDP resistance, and inhibited apoptosis in OSCC cells. In addition, lncRNA XIST acts as a molecular sponge for miR-27b-3p in OSCC. Downregulation of miR-27b-3p partially reversed the tumor suppression effect and CDDP chemosensitivity of XIST knockdown in CDDP-resistant OSCC cells. In conclusion, lncRNA XIST promotes cell proliferation and enhances resistance to CDDP in OSCC by downregulating miR-27b-3p. Copyright 2020 Biolife Sas. www.biolifesas.org.

Entities:  

Keywords:  LncRNA XIST; cisplatin; miR-27b-3p; oral squamous cell carcinoma; proliferation

Year:  2020        PMID: 33191714     DOI: 10.23812/20-222-A

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN: 0393-974X            Impact factor:   1.711


  7 in total

1.  LncRNA LHFPL3-AS1 Promotes Oral Squamous Cell Carcinoma Growth and Cisplatin Resistance Through Targeting miR-362-5p/CHSY1 Pathway.

Authors:  Jiandong Li; Xiaohu Xu; Dandan Zhang; Han Lv; Xin Lei
Journal:  Onco Targets Ther       Date:  2021-03-31       Impact factor: 4.147

Review 2.  Research progress of nanocarriers for gene therapy targeting abnormal glucose and lipid metabolism in tumors.

Authors:  Xianhu Zeng; Zhipeng Li; Chunrong Zhu; Lisa Xu; Yong Sun; Shangcong Han
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

Review 3.  Long non-coding RNA XIST: a novel oncogene in multiple cancers.

Authors:  Jun Yang; Manlong Qi; Xiang Fei; Xia Wang; Kefeng Wang
Journal:  Mol Med       Date:  2021-12-20       Impact factor: 6.354

Review 4.  Impact of Non-Coding RNAs on Chemotherapeutic Resistance in Oral Cancer.

Authors:  Karen Yamaguchi; Tomofumi Yamamoto; Junichiro Chikuda; Tatsuo Shirota; Yusuke Yamamoto
Journal:  Biomolecules       Date:  2022-02-09

Review 5.  Emerging role of lncRNAs in drug resistance mechanisms in head and neck squamous cell carcinoma.

Authors:  José A Peña-Flores; Mercedes Bermúdez; Rosalío Ramos-Payán; Carlos E Villegas-Mercado; Uriel Soto-Barreras; Daniela Muela-Campos; Alexis Álvarez-Ramírez; Brenda Pérez-Aguirre; Ana D Larrinua-Pacheco; César López-Camarillo; Jorge A López-Gutiérrez; Julio Garnica-Palazuelos; Marvin E Estrada-Macías; Juan L Cota-Quintero; Andrés A Barraza-Gómez
Journal:  Front Oncol       Date:  2022-08-01       Impact factor: 5.738

Review 6.  The role of lncRNAs and XIST in oral cancer.

Authors:  Huimin Liu; Dongxu Wang; Shaoning Kan; Ming Hao; Lu Chang; Pengxu Lu; Yangyang Liu; Ye Jin; Weiwei Liu
Journal:  Front Cell Dev Biol       Date:  2022-08-10

7.  Pan-cancer analysis of LncRNA XIST and its potential mechanisms in human cancers.

Authors:  Wei Han; Chun-Tao Shi; Jun Ma; Hua Chen; Qi-Xiang Shao; Xiao-Jiao Gao; Ying Zhou; Jing-Feng Gu; Hao-Nan Wang
Journal:  Heliyon       Date:  2022-09-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.